Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab with Chemoradiotherapy in Locally Advanced Cervical Cancer
NCT05799469Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in Cervical Cancer (CC), sponsored by Chongqing University Cancer Hospital. Planned start May 2023; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05799469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799469.